Journal
ANTICANCER RESEARCH
Volume 40, Issue 5, Pages 2941-2946Publisher
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.14272
Keywords
SF3B4; esophageal squamous cell carcinoma; poor prognostic biomarker
Categories
Funding
- MEXT [24008081, 25430111, 25461953, 25861199, 25861200, 24592005, 21229015, 4201]
- MEXT
- RIKEN Advanced Institute for Computational Science through the HPCI System Research project [hp140230]
- Ministry of Health, Labor and Welfare (MHLW) [14524362, 14525288]
- Funding Program for Next Generation World-Leading Researchers [LS094]
Ask authors/readers for more resources
Background/Aim: The spliceosome pathway, including Splicing Factor 3b Subunit 4 (SF3B4), plays an important role in carcinogenesis and progression in various cancers; however, the clinical relevance of SF3B4 in esophageal squamous cell carcinoma (ESCC) remains unknown. Patients and Methods: SF3B4 expression was evaluated by real-time reverse transcription polymerase chain reaction in 80 ESCC patients. In order to explore the mechanism of SF3B4 in ESCC, the mRNA expression and copy number of SF3B4 were obtained from TCGA and we also implemented gene set enrichment analysis (GSEA). Results: The high SF3B4 expression group (n=33) showed significantly more lymphatic permeation and poorer prognosis than the low SF3B4 expression group (n=47). GSEA revealed that high SF3B4 expression was correlated with genes associated with the transcription factor E2F and the G(2)/M checkpoint. SF3B4 expression was positively correlated with SF3B4 DNA copy number. Conclusion: Over-expression of SF3B4 may play a crucial role in the lymphatic progression of ESCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available